危急病重症病房患者的波萨可纳暴露:需要采取行动
Christina König1, Melanie Göpfert1, Stefan Kluge1
1Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 42, 20251, Hamburg, Germany.
Infection
|July 27, 2023
概括
静脉注射波萨可纳的治疗药物监测在重症患者中至关重要. 许多患者的药物水平不足,这凸显了TDM的必要性,以确保有效的抗真菌治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
背景情况:
- 波萨可纳是一种用于侵袭性真菌感染的抗真菌剂.
- 建议对口服波萨可纳进行治疗药物监测 (TDM).
- 与静脉注射 (IV) 波萨可纳一起进行TDM的需求正在增加.
研究的目的:
- 在重症患者中研究IV波萨可纳的药理学.
- 评估这种患者群体中波萨可纳暴露的可变性.
主要方法:
- 一项前性研究分析了7天内从10名危急病患者中168名波萨可纳水平.
- 使用染色学方法测量波萨可纳的度.
- 对人口统计,实验室和药物水平数据的描述性统计分析.
主要成果:
- 中位数最低波萨可纳度为0.62 mg/L.
- 58%的患者没有达到0.5毫克/升的预防目标.
- 74%的患者的低谷水平低于阿斯伯吉洛症的治疗目标1 mg/L.
结论:
- 在重症患者中,波萨可纳的暴露高度变化.
- 许多患者经历了潜在的药物度不足.
- 强烈建议使用TDM,以防止暴露不足并确保治疗的有效性.
更多相关视频
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
11.6K
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
13.0K
相关概念视频
Acute Respiratory Failure-IV
176
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
176
Acute Respiratory Failure-II
277
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
277
Acute Respiratory Failure-III
227
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
227
Acute Respiratory Failure-I
250
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
250
Acute Respiratory Failure-V
165
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
165
Pneumonia IV: Management
359
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
359
